Hangzhou Tigermed Consulting Total Assets
Hangzhou Tigermed Consulting total assets. Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) holds total assets worth CN¥28.80 Billion CNY (≈ $4.21 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Hangzhou Tigermed Consulting for the company's overall valuation and market capitalisation.
Total Assets of Hangzhou Tigermed Consulting (2009–2025)
Total assets of Hangzhou Tigermed Consulting from 2009 to 2025. This chart illustrates how Hangzhou Tigermed Consulting's total assets have evolved over time, based on quarterly financial data. See 300347 stock price for real-time trading data and today's change.
Hangzhou Tigermed Consulting - Asset Composition Analysis
Hangzhou Tigermed Consulting Total Assets Breakdown (December 2025)
Hangzhou Tigermed Consulting total assets breakdown as of December 2025. Hangzhou Tigermed Consulting's total assets of CN¥28.80 Billion consist of 21.8% current assets and 78.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 6.3% |
| Accounts Receivable | CN¥1.41 Billion | 5.0% |
| Inventory | CN¥41.50 Million | 0.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥276.31 Million | 1.0% |
| Goodwill | CN¥3.52 Billion | 12.4% |
Asset Composition Trend (2009–2025)
This chart illustrates how Hangzhou Tigermed Consulting's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 300347 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Tigermed Consulting's current assets represent 21.8% of total assets in 2025, a decrease from 55.8% in 2009.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2025, down from 25.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 17.0% in 2009.
- Asset Diversification: The largest asset category is goodwill at 12.4% of total assets.
Hangzhou Tigermed Consulting Competitors by Total Assets
Key competitors of Hangzhou Tigermed Consulting based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Diagnósticos da América S.A
SA:DASA3
|
Brazil | R$21.10 Billion |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
China | CN¥1.52 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
Hangzhou Tigermed Consulting - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.30 | 1.62 | 7.90 |
| Quick Ratio | 2.28 | 1.61 | 7.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥3.75 Billion | CN¥2.26 Billion | CN¥10.01 Billion |
Hangzhou Tigermed Consulting - Advanced Valuation Insights
This section examines the relationship between Hangzhou Tigermed Consulting's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 0.21 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | CN¥28.36 Billion |
| Market Capitalization | $5.82 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Tigermed Consulting's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hangzhou Tigermed Consulting's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hangzhou Tigermed Consulting (2009–2025)
The table below shows the annual total assets of Hangzhou Tigermed Consulting from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥28.36 Billion ≈ $4.15 Billion |
-1.09% |
| 2024-12-31 | CN¥28.67 Billion ≈ $4.20 Billion |
-3.40% |
| 2023-12-31 | CN¥29.68 Billion ≈ $4.34 Billion |
+8.14% |
| 2022-12-31 | CN¥27.45 Billion ≈ $4.02 Billion |
+15.61% |
| 2021-12-31 | CN¥23.74 Billion ≈ $3.47 Billion |
+21.71% |
| 2020-12-31 | CN¥19.51 Billion ≈ $2.85 Billion |
+157.74% |
| 2019-12-31 | CN¥7.57 Billion ≈ $1.11 Billion |
+61.78% |
| 2018-12-31 | CN¥4.68 Billion ≈ $684.54 Million |
+30.55% |
| 2017-12-31 | CN¥3.58 Billion ≈ $524.33 Million |
+50.03% |
| 2016-12-31 | CN¥2.39 Billion ≈ $349.49 Million |
+48.34% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.60 Million |
+18.59% |
| 2014-12-31 | CN¥1.36 Billion ≈ $198.66 Million |
+68.02% |
| 2013-12-31 | CN¥808.01 Million ≈ $118.24 Million |
+10.26% |
| 2012-12-31 | CN¥732.84 Million ≈ $107.24 Million |
+292.40% |
| 2011-12-31 | CN¥186.76 Million ≈ $27.33 Million |
+55.75% |
| 2010-12-31 | CN¥119.91 Million ≈ $17.55 Million |
+77.94% |
| 2009-12-31 | CN¥67.39 Million ≈ $9.86 Million |
-- |
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more